<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670226</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO15-HB-METABOMU</org_study_id>
    <secondary_id>2015-A01629-40</secondary_id>
    <secondary_id>151550B-31</secondary_id>
    <secondary_id>2016-R3</secondary_id>
    <nct_id>NCT02670226</nct_id>
  </id_info>
  <brief_title>Muscular Biomarkers in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>METABOMU</acronym>
  <official_title>Metabolomics and Transcriptomics Approaches to Identify Muscular Biomarkers in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first objective is to find some biomarkers, or a profile of biomarkers of ALS to help to&#xD;
      diagnosis. The second objective is to better understand the pathogenesis of this disease by&#xD;
      the exploration of muscle, blood and satellite cells metabolomes and transcriptomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS), the most common MND, is a fatal adult-onset&#xD;
      neuromuscular disease. Due to clinical heterogeneity and absence of biological tools to&#xD;
      diagnose ALS, the delay between the first symptoms and diagnosis averages 9-13 months. A&#xD;
      group of pathophysiological processes, including oxidative stress and glutamate-mediated&#xD;
      excitotoxicity contribute to cell death, but the triggering factor, the timing and the&#xD;
      interaction of different cellular events await elucidation [2]. Unknown pathogenesis for most&#xD;
      patients means few available treatments. The search for biomarkers that can aid diagnosis,&#xD;
      characterize phenotype, define pathophysiology, identify endpoints in trials and measure&#xD;
      disease progression is of utmost importance for the field. Some studies have advocated that&#xD;
      muscle per se may be impaired by pathogenesis of the diseases. Muscle has been poorly studied&#xD;
      and its central role in energetic metabolism suggests that this tissue, quite easily&#xD;
      available, should be more analyzed to find biomarkers and to compare muscular metabolism with&#xD;
      those of brain and overall body. Specific aims of our subjects are:&#xD;
&#xD;
      Specific aims are focused on:&#xD;
&#xD;
        1. the acquisition of metabolites profiles of the muscle, blood and satellite cells using&#xD;
           an analytical platform enable a deep exploration. For that, the use of three analytical&#xD;
           modalities (NMR, mass spectrometry coupled to GC or UPLC) ensures the best coverage of&#xD;
           the metabolite population with a high range of concentration variability and molecular&#xD;
           diversity.&#xD;
&#xD;
        2. the building of metabolites profiles models that discriminate pathological and control&#xD;
           situations.&#xD;
&#xD;
        3. the identification of metabolites implicated in the discriminant model.&#xD;
&#xD;
        4. the generation of metabolism pathways hypothesis related to the discriminant model.&#xD;
&#xD;
        5. the acquisition of transcriptomics data to confirm and add complementary results to&#xD;
           metabolomics data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic signature of muscle</measure>
    <time_frame>At baseline</time_frame>
    <description>Metabolomics profile using NMR and LC-HRMS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic signature of blood</measure>
    <time_frame>At baseline</time_frame>
    <description>Metabolomics profile using NMR and LC-HRMS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic signature of satellites cells</measure>
    <time_frame>At baseline</time_frame>
    <description>Metabolomics profile using NMR and LC-HRMS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression levels of targeted genes using transcriptomics</measure>
    <time_frame>At baseline</time_frame>
    <description>Choice of genes based on results obtained by metabolomics approaches</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention, specific to the study, is to take samples at baseline on patients without neurological disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples</intervention_name>
    <description>Blood samples, muscle biopsy</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≥ 75 years&#xD;
&#xD;
          -  ALS according to the El Escorial criteria&#xD;
&#xD;
          -  Patients affiliated to social security scheme&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Contraindication to biopsy&#xD;
&#xD;
          -  Contraindication to local anesthesia&#xD;
&#xD;
          -  Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin)&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Systemic corticosteroid treatment&#xD;
&#xD;
          -  Treatment against cramps or twitching may affect muscle metabolism&#xD;
&#xD;
        Control group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≥ 75 years&#xD;
&#xD;
          -  No neuronal disease&#xD;
&#xD;
          -  Patients affiliated to social security scheme&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Contraindication to biopsy&#xD;
&#xD;
          -  Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin)&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Systemic corticosteroid treatment&#xD;
&#xD;
          -  Treatment against cramps or twitching may affect muscle metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène BLASCO, MD</last_name>
    <role>Study Director</role>
    <affiliation>helene.blasco@univ-tours.fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de chirurgie orthopédique et traumatologique, CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Muscle metabolism</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Transcriptomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

